Correlation of FGFR2 rs2981582 polymorphisms with susceptibility to breast cancer: a case-control study in a Chinese population. Issue 10 (October 2019)

• Record Type: Journal Article
• Authors: Shu, Jin; Hui, Xuelian; Zheng, Xin; Zhao, Juan; Xu, Zhaochen; Chen, Yingpu; Lu, Chao; Li, Junling
• Is Part Of: Journal of international medical research. Volume 47:Issue 10(2019)
• Page Start: 4753
• Page End: 4763
• Publication Date: 2019-10
• Subjects: Breast cancer -- FGFR2 -- rs2981582 -- meta-analysis -- polymorphism -- fibroblast growth factor receptor 2; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/0300060519869058
• Languages: English
• ISSNs: 0300-0605

Abstract

Objective: Breast cancer (BC) is a common malignancy among women worldwide. Fibroblast growth factor receptor 2 (FGFR2) rs2981582 is reported to play a vital role in BC development. However, the relationship between them remains unclear. Methods: Ninety-five patients and 140 healthy controls were enrolled in the study. Plasma DNA was genotyped by the MassARRAY method. A meta-analysis was conducted to clarify the effect of FGFR2 polymorphism on BC risk. Results: Our case-control study results revealed a significant difference in CC, TC, and TT genotypes between patients and controls. Logistic regression analysis showed that TT and TC genotype and the dominant mode were significantly correlated with BC development [odds ratio (OR) = 1.21, 95% confidence interval (CI): 1.050–2.27; OR = 1.81, 95% CI: 1.24–2.73; OR = 2.15, 95% CI: 1.25–5.31, respectively], even after adjusting for age, body weight, drinking, smoking, and estrogen receptor status. A meta-analysis of 15 studies showed significant differences among the dominant, recessive, heterozygote, and homozygote models between patients and controls. Conclusions: Our results showed an association of FGFR2 rs2981582 polymorphism with BC in an Asian population. However, a more comprehensive study of the relationship between the polymorphism and BC is still needed.